SCHEMBL7975314

SCHEMBL7975314

CC(=O)N1CCC(C(N)=O)(c2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.55
OPRL1 P41146 1/20 0.54
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
RAB9A P51151 1/20 0.54
USP2 O75604 2/20 0.53
ALDH1A1 P00352 3/20 0.51
CYP2C19 P33261 3/20 0.51
MAPK1 P28482 2/20 0.51
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
TET3 O43151 1/20 0.50
FBXL19 Q6PCT2 1/20 0.50
CXXC5 Q7LFL8 1/20 0.50
TET1 Q8NFU7 1/20 0.50
KDM2B Q8NHM5 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13774957 0.87 CA12 (0.59) HSD11B1KMT2AMEN1RAB9AUSP2
SCHEMBL8365912 0.87 HSD11B1 (0.58) HSD11B1OPRL1KMT2AMEN1ALDH1A1
SCHEMBL20491252 0.84 HSD11B1 (0.47) HSD11B1KMT2AMEN1RAB9AALDH1A1
SCHEMBL12163076 0.84 HSD11B1 (0.51) HSD11B1KMT2AALDH1A1TET3FBXL19
SCHEMBL12227090 0.83 OPRM1 (0.61) HSD11B1OPRL1ADRA1DADRA1AADRA1B
SCHEMBL8366154 0.83 OPRL1 (0.56) HSD11B1OPRL1KMT2AMEN1ALDH1A1
SCHEMBL2702147 0.83 ALDH1A1 (0.59) HSD11B1OPRL1KMT2AALDH1A1CA12
SCHEMBL16886308 0.81 KMT2A (0.52) HSD11B1KMT2AMEN1RAB9AUSP2
SCHEMBL2722547 0.80 AKR1C1 (0.57) HSD11B1OPRL1KMT2AMEN1CYP2C9
SCHEMBL501923 0.80 AKR1C1 (0.57) HSD11B1OPRL1KMT2AMEN1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383666-B2 Pyrrole derivatives, preparation of same and therapeutic application thereof SANOFI (FR) 2013-02-26 US disclosed
US-8383666-B2 Pyrrole derivatives, preparation of same and therapeutic application thereof SANOFI (FR) 2013-02-26 US disclosed
EP-2283008-B1 PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2011-11-02 EP disclosed
US-20110144157-A1 PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2011-06-16 US disclosed
US-20110144157-A1 PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2011-06-16 US disclosed
WO-2009141533-A2 PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144157-A1 PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF ARG2, PYCR1, ARG1 HSD11B1 3327/4885OPRL1 674/4885KMT2A 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.